{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:12Z","timestamp":1786649472456,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczematous lesions. Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has recently been approved in India for moderate-to-severe AD in adults. This prospective real-world case series evaluated the effectiveness and safety of abrocitinib in patients with moderate-to-severe AD who showed an inadequate response to cyclosporine. Nine patients (five females, four males; mean age 19.44 \u00b1 7.68 years, range 10\u201334 years) were included. Three were adolescents or children in whom abrocitinib was used off-label. The mean disease duration was 13.33 \u00b1 8.06 years, and eight patients had a positive family history of AD. Prior treatments included cyclosporine, methotrexate, and systemic corticosteroids. Abrocitinib was prescribed at a mean dose of 177.77 \u00b1 44.09 mg daily (seven patients received 200 mg, two received 100 mg). Effectiveness was assessed at baseline and weeks 2, 4, 8, and 12 using the Eczema Area and Severity Index (EASI), Investigator\u2019s Global Assessment (IGA), and Peak Pruritus Numerical Rating Scale (PP-NRS). Significant and progressive reductions were observed in all scores. Mean EASI decreased from 48.22 \u00b1 7.88 at baseline to 6.33 \u00b1 3.35 at week 12 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001). IGA scores improved from 4 to 1.22 \u00b1 0.44, while PP-NRS declined from 8.44 \u00b1 0.52 to 2 \u00b1 0.86 by week 12, with significance evident early in treatment. Most patients demonstrated good adherence, and dose adjustments were required in some cases. One patient developed mild thrombocytopenia. Abrocitinib demonstrated rapid, significant clinical improvement and was generally well-tolerated, supporting its role as an effective option for moderate-to-severe AD, particularly in patients with inadequate response to cyclosporine.\n                  <\/jats:p>","DOI":"10.4103\/ijd.ijd_516_25","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:26:24Z","timestamp":1776785184000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent"],"prefix":"10.4103","volume":"71","author":[{"given":"Abhishek","family":"De","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Rochester, Minnesota, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K. Shahriar","family":"Ahmed","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Maryland Baltimore, Midtown Campus, Baltimore, MD, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipan","family":"Dhar","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital, Delhi Cantt, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"R1-20260501","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4103\/ijd.ijd_181_23","article-title":"Current burden of atopic dermatitis in India: A systematic literature review","volume":"68","author":"De","year":"2023","journal-title":"Indian J Dermatol"},{"key":"R2-20260501","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/CCID.S327593","article-title":"Burden of disease, unmet needs in the diagnosis and management of atopic dermatitis: An Indian expert consensus","volume":"14","author":"Rajagopalan","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R3-20260501","first-page":"1","article-title":"Use of Janus kinase inhibitors in atopic dermatitis\u2013an update","volume":"17","author":"Dhar","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R4-20260501","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (jade mono-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"R5-20260501","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) regimen phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R6-20260501","doi-asserted-by":"crossref","first-page":"2411855","DOI":"10.1080\/09546634.2024.2411855","article-title":"Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: Results from a 16-week real-world multicenter retrospective study\u2013il AD (Italian landscape atopic dermatitis)","volume":"35","author":"Gargiulo","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"R7-20260501","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/jdv.19378","article-title":"Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis","volume":"37","author":"Olydam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20260501","doi-asserted-by":"crossref","first-page":"e42231","DOI":"10.1097\/MD.0000000000042231","article-title":"Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China","volume":"104","author":"Liang","year":"2025","journal-title":"Medicine (Baltimore)"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_516_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:35Z","timestamp":1786647275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_516_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_516_25","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2025-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}